Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant

Table 4 Distribution of patients according to cytoplasmic programmed cell death protein 1 ligand 1 + immune cell score and the clinical and pathological characteristics of patients with breast cancer

Breast cancer characteristics	PDCD1 LG1+ IC score						Р value
	< 10%		≥ 10% and < 30%		≥ 30%
	n	%	n	%	n	%
T stage
Тin situ	2	50.0	2	50.0	0	0	0.035a
Т1в	4	36.4	5	45.4	2	18.2
Т1с	59	66.3	18	20.2	12	13.5
Т2	36	81.8	3	6.8	5	11.4
N stage
N0	58	71.6	11	13.6	12	14.8	0.488
N1	31	66.0	11	24.4	5	10.6
N2-3	12	60.0	6	30.0	2	10.0
Clinical stage
0	2	50.0	2	50.0	0	0	0.158
I (IA)	38	71.7	6	11.3	9	17.0
IIA	35	63.6	14	25.4	6	10.9
IIB	15	88.2	0	0	2	11.8
IIIA	9	60.0	4	26.7	2	13.3
IIIB	2	50.0	2	50.0	0	0
Tumor grade
G1	10	62.5	6	37.5	0	0	0.018a
G2	64	73.6	15	17.2	8	9.2
G3	27	60.0	7	15.6	11	24.4
Lymphovascular invasion
Absent	60	71.4	15	17.9	9	10.7	0.581
Present	41	64.1	13	20.3	10	15.6
Perineural invasion
Absent	79	68.7	24	20.9	12	10.4	0.185
Present	22	66.7	4	12.1	7	21.2
Intraductal component
Absent	73	68.2	21	19.6	13	12.2	0.885
Present	28	68.3	7	17.1	6	14.6
Estrogen receptor status
Negative	5	31.25	5	31.25	6	37.5	0.0012a
Positive	96	72.7	23	17.4	13	9.9
Progesterone receptor status
Negative	25	61.0	7	17.1	9	21.9	0.122
Positive	76	71.0	21	19.6	10	9.4
HER2 status
Negative	99	77.3	23	18.0	6	4.7	0.0000a
Positive	2	10.0	5	25.0	13	65.0
Breast cancer subtypes
Luminal A	42	75.0	8	14.3	6	10.7	0.0000a
Luminal B HER2-	54	81.8	12	18.2	0	0
Luminal B HER2+	0	0	3	30	7	70
Nonluminal HER2+	2	20.0	2	20.0	6	60.0
TNBC	3	50.0	3	50.0	0	0

^aP < 0.05 was considered statistically significant.

Statistical test: χ². ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2; PR: Progesterone receptor; TNBC: Triple negative breast cancer; cPDCD1 LG1: Cytoplasmic programmed cell death protein 1 ligand 1; IC: Immune cells.